Related references
Note: Only part of the references are listed.Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis
Gary R. Lichtenstein et al.
INFLAMMATORY BOWEL DISEASES (2014)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2014)
Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis
B. Flourie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study
Mamoru Watanabe et al.
INFLAMMATORY BOWEL DISEASES (2013)
Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis
Geert D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials
Ying Zhu et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis
A. Barney Hawthorne et al.
INFLAMMATORY BOWEL DISEASES (2012)
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis
Brian G. Feagan et al.
INFLAMMATORY BOWEL DISEASES (2012)
Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: A meta-analysis
Jin Lu Tong et al.
JOURNAL OF DIGESTIVE DISEASES (2012)
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
W. Kruis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts
S. V. Kane et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2010)
Clinical Trial: A Novel High-dose 1 g Mesalamine Suppository (Salofalk) Once Daily Is as Efficacious as a 500-mg Suppository Thrice Daily in Active Ulcerative Proctitis
Tilo Andus et al.
INFLAMMATORY BOWEL DISEASES (2010)
Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial
Sunanda Kane
Patient Preference and Adherence (2010)
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®
C. Prantera et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Axel U. Dignass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
W. Kruis et al.
GUT (2009)
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M. A. Kamm et al.
GUT (2008)
Predictors of medication adherence in inflammatory bowel disease
Jason P. Ediger et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers
Peggy Gandia et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis
S. B. Hanauer
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Systematic review: adherence issues in the treatment of ulcerative colitis
SV Kane
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: A multicenter randomized study
M Lamet et al.
INFLAMMATORY BOWEL DISEASES (2005)
Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters
FN Hussain et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
